SAN FRANCISCO, Aug. 21 /PRNewswire-FirstCall/ -- Medizone
International, Inc. (Pink Sheets: MZEI) announces the appointment of
Michael E. Shannon, M.A., M.Sc., M.D. to its Board of Directors. Dr.
Shannon received his medical degree from Queen's University in Canada,
which included advanced training in surgery and sports medicine. He also
holds post-graduate degrees in neurochemistry and physiology. He has been
actively engaged in applied medical research within these areas for over 27
years. He served in the Canadian Forces for 31 years retiring at the rank
of Commodore (Brigadier General equivalent) as Deputy Surgeon General for
Canada. During the first Gulf War, Dr. Shannon served as the senior medical
liaison officer for all of the Canadian forces. In 1996 he assumed
responsibilities within Health Canada for re-organizing the Canadian blood
system. Working with both the provincial and federal governments, he
oversaw the development of a new corporate entity dedicated exclusively to
the management of blood services in Canada. He was then appointed Director
General for the Laboratory Centre for Disease Control, a position he held
for three years. In December 2000, Dr. Shannon left the Canadian federal
government to pursue a new career in industry. In that capacity he
simultaneously directed a phase III clinical trial in Canada, the United
States and Great Britain for an artificial blood substitute product.
Following completion of that work he was asked to accept a special
assignment with the Canadian Federal Government Auditor General's office.
His assignment was to conduct a cost benefit analysis of all government
sponsored pharmacare programs and make recommendations directly to the
Parliament of Canada. His assignment and presentation to Parliament on that
project was completed in November 2004. Dr. Shannon recently worked on a
special project assignment as Senior Medical Advisor to the Canadian Public
Health Agency. His assignment was to review and help
|SOURCE Medizone International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved